Primary cardiac sarcomas are extremely rare. They account for 8% of all pnrmary cardiac tumours resected (Blondeau. 1990 ). but the necroscopic incidence is threefold that of operated cases (Chomette et al, 1985) . All histological types have been described. and angiosarcoma. representing 30-45% of cases. is the most commonly described (McAllister et al. 1979 : Silverman, 1980 . During the course of the disease, the presenting symptoms (dyspnoea, chest pain, congestive heart failure, palpitations, fever. or myalgia) appear late, and these delayed manifestations generally reflect a wide local extension with severe cardiac damage (Goodwin. 1968) . Even though distant metastasis frequently occurs, the clinical course in patients with primary cardiac sarcoma is related to local tumour extension (Becker et al. 1985) .
Since the first surgical resection of a cardiac tumour was reported (Crafoord, 1955) . surgery has become the standard firstline treatment, able to provide substantial palliation of symptoms and prolong survival (Dein et al, 1987) . However, most patients present with marginally resectable or technically non-resectable disease at diagnosis, and patients surviving 2 years after local excision are rarely reported (Murphy et al. 1990 : Moggio et al. 1992 .
Given the likely inadequacy of surgical margins and the high risk of distant metastasis, both adjuvant radiotherapy and systemic chemotherapy have been recommended. Unfortunately May 1998 Coespdece tc, A omrbart-Cussac, Servio Oncobgia Medica, Insrtuto Vanciano de Oncolkoga C/P Beltran Baguena 9, Vaknca 46021, Spain of these multimodality therapies are disappointing. In two recent retrospective series (Putman et al. 1991 : Burke et al. 1992 . surgical resection was the only factor found to improve survival, with a suggested enhancement conferred by post-operative chemotherapy.
This study analyses the patterns of relapse and survival of 15 patients who have undergone resection of a primary cardiac sarcoma. together with an adjuvant anthracycline-based chemotherapy regimen at the same institution.
MATERIAL AND METHODS
From October 1978 to December 1995. 19 patients were admitted to our institution with an initial diagnosis of primary malignant cardiac sarcoma. Patients were referred for additional treatment by French or Italian cardiovascular or thoracic institutions.
Histological diagnosis was made on the operative specimens and all slides were reviewed by the pathology department of the Institut Gustave Roussy. France. Diagnostic criteria excluded patients with a history of soft-tissue or bone sarcoma. Surgery with any macroscopic or microscopic involvement of margins was classified as incomplete. Complete resection was defined by the absence of involvement of all margins. The medical record of each patient was reviewed and routine demographic data recorded until 1 March 1998. Lost follow-up information on two patients was obtained by corresponding with their physicians.
Survival was calculated using the Kaplan-Meier method (Kaplan and Meier, 1958) . Groups were compared using the generalized Wilcoxon-Gehan test (Gehan et al. 1965) . All P-values resulted from two-sided tests. Time to progression was calculated from the date of surgical resection to the date of first relapse. Time to local failure was determined from the date of resection to the date of local relapse. Survival was calculated from the date of the first operation to the date of last follow-up information.
RESULTS
Four patients with primary cardiac sarcoma (PCS) have been excluded from the analysis. Two of these had an unresectable tumour. suitable for biopsy only; death occurred 2 and 6 months after diagnosis. The other two patients presented with synchronous lung or cutaneous metastases. Local resection was complete in one. but incomplete in the other. Neither patient responded to an anthracycline-based chemotherapy regimen: in both cases the cause of death was local progression 5 and 12 mWonths after surgery.
The characteristics of the remaining 11 male and four female patients are listed in Table 1 . The median age was 45 years (range 16-66). Six patients (40%) had an angiosarcoma. three a malignant fibrous histiocytoma. two a leiomyosarcoma. two a rhabdomyosarcoma. and the remaining two had a liposarcoma and a synovialsarcoma-The chamber of origin was associated with the histological subtype: angiosarcoma commonly originated in the right side of the heart (right atrium. n = 4; left atrium. n = 1; right atrium and ventricle. n = 1). All the other histological types but one developed on the left side of the heart (left atrium. n = 7: left atrium and ventricle. n = 1: right atrium. n = 1). All patients presented symptoms at diagnosis; cardiac manifestations varied from chest pain to cardiac heart failure or constrictive pericarditis. One patient developed a tumour embolus as the first symptom. A patient with an implanted metallic mitral valve (patient 11) developed a malignant fibrous histiocytoma adjacent to this valve.
A complete resection was achieved in six patients. but was incomplete in nine (four with microscopical residual disease and five with gross residual tumour). Five out of six patients with an angiosarcoma and four out of nine with other histological types had incomplete resections.
After initial debulking surgery, all patients had a performance status (PS) of 0-1 (PS 0. eight patients: PS 1. seven patients) without severe congestive heart failure or obstructive symptoms.
documented by a normnal left ventricular ejection fraction (LVEF).
Three out of four patients with gross residual tumour. along with seven other patients, underwent a chest scan or a cardiac magnetic resonance examination before chemotherapy. Adjuvant chemotherapy started within 6 weeks of surgery and included (Table 1) : cyclophosphamide. doxorubicin. vincristine and dacarbazine (CYVADIC regimen. n = 4): ifosfamide and doxorubicin (Al regimen. n = 9): doxorubicin. methotrexate and vincristine (AMV regimen. n = 1): and doxorubicine alone (n = 1). The mean number of chemotherapy courses for the whole group was four (range 1-6). Chemotherapy was stopped in one patient after three cycles (cumulative doxorubicin dose 225 mg mr-) because of impairment of LVEF. In five patients in whom resection was incomplete. a local and/or distant recurrence was observed during adjuvant chemotherapy. The nine patients who completed the planned chemotherapy received a median doxorubicin cumulative dose of 300 mg m-2 (range 250-360 mg m-2). Additional mediastinal adjuvant radiotherapy (50 Gy) was delivered to one patient in whom surgical resection was incomplete.
Twelve patients (80%) developed local recurrence. which was the first tumour event in eight of them. but in four was synchronous with metastatic progression. The median disease-free interval for local relapse was 11 months (range 1-25). Distant metastases were observed in nine patients after a median time of 7 months (range 1-65). The metastatic sites involved were the lung (n = 7). soft tissue (n = 3). bone (n = 2). liver (n = 1). abdomen (n = 1) and the central nervous system (n = 1). Only two patients were free of disease at the time of analysis. with a follow-up of 25 and 27 months. The median disease-free progression interval (DFI) was 10 months (range 1-25).
Patients with primary cardiac angiosarcoma had a significantly shorter DFI than patients with other histological types (P < 0.05): the median DFI was 4 months (range 1-12) and 13 months (range 4-25) for vascular and non-vascular sarcoma respectively.
At the first sign of relapse. different palliative procedures were implemented. Further chemotherapy regimens were administered British Journal of Cancer (1998) At the time of the analysis, 12 patients (80%) have died. The cause of death was related to locoregional progression in 11. One patient, who had no local recurrence, died of pulmonary metastases 5 months after surgery. The median overall survival was 12 months (range 2-68). and the 2-year overall survival rate was 19% (Figure 1) . Survival was significandly shorter in patients with angiosarcoma than in the rest of the population (7 vs 18 months. P = 0.04) as shown in Figure 2 . The six patients with a completely resected cardiac sarcoma had a significandly longer survival rate than the nine with residual disease (Figure 3) , with a median survival of 22 months and 7 months respectively (P = 0.02).
DISCUSSION
Primary sarcoma of the heart is rare with a dismal short-term prognosis. Surgery is the only treatment capable of improving outcome even after palliative resection, but long-term survivors are still anecdotal. Sporadic cases of long-term survivors treated with radiation therapy (Stevens et al. 1992 ) and/or chemotherapy (Potter et (Demny. 1996) .
The goal of this retrospective study was to analyse the potential benefit of post-operative doxorubicin-containing chemotherapy in healthy patients with PCS having undergone local resection.
Patients with unresectable tumours. low performance status or any contraindication to anthracyclines were excluded. Doxorubicin was used in most cases combined with ifosfamide or dacarbazine. two active regimrens in advanced soft-tissue sarcomas (Antman et al, 1993; Edmonson et al. 1993; Santoro et al. 1995) . Chemotherapy was started within 6 weeks of surgery. Thus, this series represents a selected group of PCS patients treated by surgery and optimal chemotherapy. with a hypothetically more favourable outcome than in any other published study. Despite this. results are disappointing. The median interval to first relapse (local or metastatic) was 10 months and the median survival was 12 months. Only three patients were alive at the time of analysis. one with metastatic disease. These results move towards those obtained by another series (Putman et al, 1989) who achieved an overall survival rate of 14% at 2 years in a less favourable population, including patients with non-resected or untreated disease.
The type of sarcoma was the only histological finding correlating with progression-free survival and overall survival. Patients with cardiac angiosarcoma had the least favourable outcome because all relapsed and died. 83% of them in the first year. None of the published series stressed this point, but Putman et al (1989) reported no surviving patients with angiosarcoma 18 months after diagnosis as opposed to 42% (5 out of 12 patients) with other histological types. In common sarcomas (visceral or soft tissue), angiosarcomas have a poor prognosis irrespective of primary site and histological grade. A retrospective analysis on 1100 patients with resected sarcoma (Hashimoto et al. 1992) reported an overall survival of 14% at 5 years for angiosarcoma. as opposed to 70% for patients with myxoid liposarcoma. In PCS. a previous study (Burke et al. 1991 ) demonstrated a relationship between histological features, for example high mitotic activity or tumour necrosis and dismal outcome. Chemotherapy in primary cardiac sarcomas 1627
The quality of initial tumour debulking was predictive of a disease-free and status survival in our study. One series (Putnam et al. 1991) reported an overall survival of 24 months for patients having undergone wide resection of tumours. compared with only 10 months in all other patients. Similarly. in the univariate analysis. complete or wide excision was associated with an increased survival in the Anned Forces Institute series (Burke et al. 1992) The extent of the surgical procedure seemed related to histological type because angiosarcoma patients had more incomplete resections (five out of six). whereas patients with non-vascular sarcomas had more completely resected tumour (five out of nine).
This point did not reach statistical significance probably because of the small number of patients (P = 0.1). However. the relatively high incidence of pericardic involvement and multifocal presentation of angiosarcomas could partially account for the inadequate local control of these tumours.
Local relapse was the first and most common type of recurrence. Only one patient. who died early because of pulmonary metastases. had no local failure. However. distant metastases were generally detected at the same time or a few months after local recurrence. The same pattern of relapse is observed in patients with marginally or incompletely resected high-grade soft-tissue sarcomas (Choong et al. 1995 : Lewis et al. 1997 .
Primary cardiac sarcomas can be divided into two groups according to the histological subtype. Cardiac angiosarcomas tend to anse in the right chambers of the heart. thus delaying symptoms (Janigan et al. 1986 ). They are initially larger tumours and carry a poor prognosis whatever the quality of initial surgical resection. which is generally incomplete (Potter et al. 1989 ). These factors. compounded by the high frequency of distant metastasis at diagnosis (Herrmann et al. 1992 ). contribute to the limited duration of survival. Moreover. these tumours are usually resistant to conventional cytotoxic agents as observed in our patients. New effective drugs. and innovative strategies such as inmunotherapy. antiangiogenic factors or intensive chemotherapy regimens need to be tested on these high-grade aggressive tumours.
In contrast. non-vascular cardiac sarcomas appear to be less aggressive: they arise predominantly in the left chambers of the heart and present as an intracavity mass. The most frequent cause of relapse in our series was local progression. These tumours should undergo optimal resection. and neoadjuvant chemotherapy could be incorporated in treatment. Adjuvant radiotherapy seems mandatory if the aim is to preclude local relapse. but the best option for selected patients could be an orthotopic cardiac transplant.
In recent years. orthotopic heart transplant has been proposed to only a few unselected patients with primary cardiac sarcoma (Goldstein et al. 1995) . namely patients with locally advanced tumours (Siebenmann et al. 1990) or angiosarcoma (Armitage et al. 1990 : Crespo et al. 1993 ). Most of these cases rapidly developed distant metastases thereafter. and long-term survivors are still rare (Aravot et al. 1989 ). Based on our data. heart transplantation can be proposed to patients with widely resected non-angiosarcoma cardiac tumours with no obvious distant metastasis. In conclusion and despite the dismal prognosis. a benefit in quality of life and sur ival has been observed over the last decade in patients with PCS. This improvement is based on (i) the routine use of echocardiography. allowing a more accurate diagnosis: (ii) the development of new surgical techniques which have improved the quality and number of cardiac resections (Perchinsky et al. 1997): and. perhaps. (iii) the optimization of chemotherapy regimens including anthracyclins and high-dose ifosfamide (Le Cesne et al. 1996 ).
In the next years. oncologists will be concerned about additional treatments in patients after optimal PCS resection. The impact of conventional chemotherapy cannot be determined in this small and retrospective study. but a need for more active systemic treatments and/or new therapeutic approaches emerged from the outcome of these patients.
